Abstract
The assessment of the effect of transplant therapy for neurological disease in humans is complex. This is particularly the case for the neurodegenerative conditions that are candidates for transplant therapy including Parkinson’s disease, Huntington’s disease, and Alzheimer’s disease. These diseasees are characterized by disturbances of higher order neurologic function, which are complex and often not easily reduced to numerical values. Most rating scales for these conditions are not linear. They also often rely on the subjective judgment of the examiner. The neurologic deficits of neurodegenerative disorders also change with the emotional state of the patient; for example, the enthusiasm and optimism surrounding a transplant procedure may be sufficient to improve the motor performance of a patient with Parkinson’s disease. For the preceding reasons, the use of positron emission tomography (PET) as an objective measure of the degree of neurologic function improves the ability of investigators to determine the effect and measure objectively the results of transplant therapy in humans.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Laitinen, L. V., Bergenheim, T., and Hariz, M. I. (1992) Leksell’s posteroventral pallidotomy in the treatment of Parkinson’s disease. J. Neurosurg. 76, 53–61.
Herscovitch, P. (1990) Principles of positron emission tomography, in Functional Imaging in Movement Disorders ( Martin, W. R. W., ed.), CRC Press, Boca Raton, FL, pp. 1–46.
Garnett, E. S., Firnau, G., and Nahmias, C. (1983) Dopamine visualised in the basal ganglia of living man. Nature 305, 137–138.
Melega, W. P., Grafton, S. T., Huang, S., Satyamurthy, N., Phelps, M. E., and Barrio, J. R. (1991) L-6-[18F]fluoro-DOPA metabolism in monkeys and humans: biochemical parameters for the formulation of tracer kinetic models with positron emission tomography. J. Cereb. Blood Flow Metab. 11, 890–897.
Snow, B. J., Tooyama, I., McGeer, E. G., Yamada, T., Caine, D. B., Takahashi, H., et al. (1993) Correlations in humans between premortem PET [18F]fluorodopa uptake, postmortem dopaminergic cell counts and striatal dopamine levels. Ann. Neurol. 34, 324–330.
Pate, B. D., Kawamata, T., Yamada, T., McGeer, E. G., Hewitt, K. A., Snow, B. J., et al. (1993) Correlation of striatal fluorodopa uptake in the MPTP-monkey with dopaminergic indices. Ann. Neurol. 34, 331–338.
Vingerhoets, F. J., Schulzer, M., Calne, D. B., and Snow, B. J. (1996) Which clinical sign of Parkinson’s disease best reflects the nigrostriatal lesion? Ann. Neurol. 41, 58–64.
Sawle, G. V., Brooks, D. J., Ibanez, V., and Frackowiak, R. S. J. (1990) Striatal D2 receptor density is inversely proportional to dopa uptake in untreated hemi-parkinson’s disease. J. Neurol. Neurosurg. Psychiatry 53, 177–182.
Lindvall, O., Backlund, E., Farde, L., Sedvall, G., Freedman, R., Hoffer, B. J., et al. (1987) Transplantation in Parkinson’s disease: two cases of adrenal medullary grafts to the putamen. Ann. Neurol. 22, 457–468.
Brooks, D. J., Ibanez, V., Sawle, G. V., Playford, E. D., Quinn, N., Mathias, C. J., et al. (1992) Striatal D2 receptor status in patients with Parkinson’s disease, striatonigral degeneration, and progressive supranuclear palsy, measured with [11C]-raclopride and positron emission tomography. Ann. Neurol. 31, 184–192.
Uitti, R. J. and Snow, B. J. (1994) Positron emission tomography measurements of striatal D2 receptors in untreated Parkinson’s disease patients with followup after 6 months treatment with Sinemet or Sinemet CR. Movement Disord. 9, 119.
Frost, J. J., Rosier, A. J., Reich, S. G., Smith, J. S., Ehlers, M. D., Snyder, S. H., et al. (1993) Positron emission tomographic imaging of the dopamine transporter with 11C-Win35,428 reveals marked declines in mild Parkinson’s disease. Ann. Neurol. 34, 423–431.
Kilbourn, M. R., DaSilva, J. N., Frey, K. A., Koeppe, R. A., and Kuhl, D. E. (1993) In vivo imaging of vesicular monoamine transporters in human brain using [11C]tetrabenazine and PET. J. Neurochem. 60, 2315–2318.
Guttman, M., Burns, R. S., Martin, W. R. W., Peppard, R. F., Adam, M. J., Ruth, T. J., et al. (1989) PET studies of parkinsonian patients treated with autologous adrenal transplants. Can. J. Neurol. Sci. 16, 305–309.
Yong, V. W., Guttman, M., Kim, S. U., Caine, D. B., Turnbull, I., Watabe, K., et al. (1989) Transplantation of human sympathetic neurons and adrenal chromaffin cells into parkinsonian monkeys: no reversal of clinical symptoms. J. Neurol. Sci. 94, 51–67.
Goetz, C. G., Stebbins, G. T., III, Kiawans, H. L., Koller, W. C., Grossman, R. G., Bakay, R. A., et al. (1991) United Parkinson Foundation Neurotranspiantation Registry on adrenal medullary transplants: presurgical, and 1- and 2-year follow-up. Neurology 41, 1719–1722.
Landau, W. M. (1993) Clinical neuromythology X. Faithful fashion: survival status of the brain transplant cure for parkinsonism. Neurology 43, 611 649.
Martin, W. R. W. and Perlmutter, J. S. (1994) Assessment of fetal tissue transplantation in Parkinson’s disease: does PET play a role? Neurology 44, 1777–1780.
Lindvall, O., Rehncrona, S., Brundin, P., Gustavii, B., Astedt, B., Widner, H., et al. (1989) Human fetal dopamine neurons grafted into the striatum in two patients with severe Parkinson’s disease: a detailed account of methodology, and a six month follow-up. Arch. Neurol. 46, 615–631.
Lindvall, O., Brundin, P., Widner, H., Rehncrona, S., Gustavii, B., Frackowiak, R. S. J., et al. (1990) Grafts of fetal dopamine neurons survive and improve motor function in Parkinson’s disease. Science 247, 574–577.
Widner, H., Tetrud, J., Rehncrona, S., Snow, B., Brundin, P., Gustavii, B., et al. (1992) Bilateral fetal mesencephalic grafting in two patients with parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). N. Engl. J. Med. 327, 1556–1563.
Freed, C. R., Breeze, R. E., Rosenberg, N. L., Schneck, S. A., Kriek, E., Qi, J. X., et al. (1992) Survival of implanted fetal dopamine cells and neurologic improvement 12 to 46 months after transplantation for Parkinson’s disease. N. Engl. J. Med. 327, 1549–1555.
Spencer, D. D., Robbins, R. J., Naftolin, F., Marek, K. L., Vollmer, T., Leranth, C., et al. (1992) Unilateral transplantation of human fetal mesencephalic tissue into the caudate nucleus of patients with Parkinson’s disease. N. Engl. J. Med. 327, 1541–1548.
Remy, P., Samson, Y., Hantraye, P., Fontaine, A., Defer, G., Mangin, J., et al. (1995) Clinical correlates of [18Flfluorodopa uptake in five grafted parkinsonian patients. Ann. Neurol. 38, 580–588.
Freeman, T., Hauser, R. A., Sanberg, P. R., Snow, B. J., Vingerhoets, F. J. G., and Olanow, C. W. (1994) Fetal transplantation in Parkinson’s disease. Neurology 22 (Suppl. 2), A324.
Lindvall, O. (1994) Neural transplantation in Parkinson’s disease, in Functional Neural Transplantation ( Dunnett, S. B. and Björklund, A., eds.), Raven, New York, pp. 103–137.
Doucet, G., Brundin, P., Descarries, L., and Björklund, A. (1990) Effect of prior denervation on survival and fiber outgrowth from intrastriatal fetal mesencephalic grafts. Eur. J. Neurosci. 2, 279–290.
Miletich, R. S., Bankiewicz, K. S., Plunkett, R., Finn, R., Jacobs, G., Baldwin, P., et al. (1988) l-[18F)6fluorodopa PET imaging of catecholaminergic tissue implants in hemiparkinsonian monkeys. Neurology 38, 145.
Kordower, J. H., Freeman, T. B., Snow, B. J., Vingerhoets, F. J., Mufson, E. J., Sanberg, P. R., et al. (1995) Neuropathological evidence of graft survival and striatal reinnervation after the transplantation of fetal mesencephalic tissue in a patient with Parkinson’s disease. N. Engl. J. Med. 332, 1118–1124.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1998 Springer Science+Business Media New York
About this chapter
Cite this chapter
Snow, B.J. (1998). PET Studies of Transplantation Therapy. In: Freeman, T.B., Widner, H. (eds) Cell Transplantation for Neurological Disorders. Contemporary Neuroscience. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-476-4_4
Download citation
DOI: https://doi.org/10.1007/978-1-59259-476-4_4
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-61737-043-4
Online ISBN: 978-1-59259-476-4
eBook Packages: Springer Book Archive